- Investing Ideas
- Chinese Pharmaceuticals & Biotech Undervalued based on future growth
Chinese Pharmaceuticals & Biotech Undervalued based on future growth
Results
6
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
6 companies
Zhejiang Medicine
Market Cap: CN¥11.2b
Manufactures and sells life nutrition and pharmaceuticals products in China and internationally.
600216
CN¥11.77
7D
-1.1%
1Y
-19.7%
Zhejiang Jolly PharmaceuticalLTD
Market Cap: CN¥9.0b
Engages in the research, production, and marketing of Chinese medicinal products in the People’s Republic of China and internationally.
300181
CN¥13.04
7D
-2.6%
1Y
-24.3%
Aurisco PharmaceuticalLtd
Market Cap: CN¥7.8b
Engages in the research, development, production and sales of special complex APIs, pharmaceutical intermediates and preparations worldwide.
605116
CN¥19.41
7D
3.1%
1Y
-8.0%
Shandong Wit Dyne HealthLtd
Market Cap: CN¥6.4b
Engages in the pharmaceutical business in China.
000915
CN¥27.24
7D
1.1%
1Y
-5.4%
Hunan Fangsheng Pharmaceutical
Market Cap: CN¥4.1b
Engages in research, develops, produces, and sells traditional Chinese medicine industry and chemical pharmaceutical products in China.
603998
CN¥9.32
7D
-3.1%
1Y
-7.5%
Bide Pharmatech
Market Cap: CN¥3.8b
Engages in the research, development, production, and sale of pharmaceutical products in China.
688073
CN¥44.63
7D
-2.0%
1Y
-6.0%